Zydus Cadila awaits product approvals worth US $6 billion
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
The commercial production in the SML was started in November 1989.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
The phase 3 clinical trial of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double blind, parallel group placebo controlled study in India.
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
This vaccination programme is based on the principles of priority groups to be vaccinated and health care workers both in the government and private sectors including ICDS workers will receive the vaccine during this phase.
The company is expecting tremendous growth and a better quarterly performance
Viruses evolve into new strains when there is a change to their genetic composition.
The Phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.
Subscribe To Our Newsletter & Stay Updated